Literature DB >> 19230716

Astragalus polysaccharides inhibited diabetic cardiomyopathy in hamsters depending on suppression of heart chymase activation.

Wei Chen1, Yi-Ming Li, Mao-Hua Yu.   

Abstract

Diabetic cardiomyopathy is associated with high morbidity and mortality of heart failure. Overactivation of the local chymase-Ang II system plays a dominant role in diabetic cardiomyopathy. Astragalus polysaccharide (APS) is used in traditional Chinese medicine to boost immunity. To study the effect of APS on local system of chymase-Ang II in diabetic cardiomyopathy, we investigated APS/normal saline (NS)-administrated streptozotocin-induced diabetic hamsters. After APS/NS administration at a dose of 1 g/kg per day for 10 weeks, hemodynamic parameters, levels of insulin (INS), C-peptide (C-P), glycosylated serum protein (GSP), lipoproteins, myocardial enzymes, and Ang II (plasma and myocardial) were tested; myocardial collagen (type I and III), myocardial ultrastructure, and activities of matrix metalloproteinase (MMPs) were measured; activities and expression of cardiac chymase and ACE were detected by using quantitative real-time RT-PCR and RIA; protein expression of cardiac phosphoric extracellular signal-regulated kinase 1/2 (p-ERK1/2) was measured by Western blot. AP-administrated diabetic hamsters had lower levels of GSP, lipoproteins, myocardial enzymes, myocardial Ang II, expression of collagen I and I/ III, activities of pro-MMP-2 and MMP-2, activities and expression of chymase, and expression of p-ERK1/2 than NS-administrated diabetic hamsters and could better protect the myocardial ultrastructure. There was no difference in hemodynamic parameters between two groups. These results indicate that APS could inhibit diabetic cardiomyopathy in hamsters depending on the suppression of the local cardiac chymase-Ang II system.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19230716     DOI: 10.1016/j.jdiacomp.2008.12.003

Source DB:  PubMed          Journal:  J Diabetes Complications        ISSN: 1056-8727            Impact factor:   2.852


  17 in total

1.  Improvement of myocardial glycolipid metabolic disorder in diabetic hamster with Astragalus polysaccharides treatment.

Authors:  Wei Chen; Yan-Ping Xia; Wen-Jie Chen; Mao-Hua Yu; Yi-Ming Li; Hong-Ying Ye
Journal:  Mol Biol Rep       Date:  2012-03-17       Impact factor: 2.316

2.  Molecular cloning, characterization and expression of a chalcone reductase gene from Astragalus membranaceus Bge. var. mongholicus (Bge.) Hsiao.

Authors:  Rong-Yan Xu; Peng Nan; Haiyun Pan; Tongshui Zhou; Jiakuan Chen
Journal:  Mol Biol Rep       Date:  2011-06-07       Impact factor: 2.316

3.  Astragalus polysaccharide injection integrated with vinorelbine and cisplatin for patients with advanced non-small cell lung cancer: effects on quality of life and survival.

Authors:  Li Guo; Shu-Ping Bai; Ling Zhao; Xiao-Hong Wang
Journal:  Med Oncol       Date:  2011-09-18       Impact factor: 3.064

4.  Effect of astragaloside IV on diabetic gastric mucosa in vivo and in vitro.

Authors:  Ningding Wang; Frederick Siu; Yongbin Zhang
Journal:  Am J Transl Res       Date:  2017-11-15       Impact factor: 4.060

5.  Administration of a decoction of sucrose- and polysaccharide-rich radix astragali (huang qi) ameliorated insulin resistance and Fatty liver but affected Beta-cell function in type 2 diabetic rats.

Authors:  Yi-Chen Juan; Yao-Haur Kuo; Chia-Chuan Chang; Li-Jie Zhang; Yan-Yu Lin; Chia-Yun Hsu; Hui-Kang Liu
Journal:  Evid Based Complement Alternat Med       Date:  2011-01-10       Impact factor: 2.629

6.  Therapy with Astragalus polysaccharides rescues lipotoxic cardiomyopathy in MHC-PPARα mice.

Authors:  Wei Chen; Wenjie Chen; Yanping Xia; Xuelan Zhao; Hao Wang; Maohua Yu; Yiming Li; Hongying Ye; Yu Zhang
Journal:  Mol Biol Rep       Date:  2012-11-30       Impact factor: 2.316

7.  Astragalus polysaccharides attenuate postburn sepsis via inhibiting negative immunoregulation of CD4+ CD25(high) T cells.

Authors:  Qing-yang Liu; Yong-ming Yao; Yan Yu; Ning Dong; Zhi-yong Sheng
Journal:  PLoS One       Date:  2011-06-15       Impact factor: 3.240

8.  Astragalus polysaccharides improve cardiomyopathy in STZ-induced diabetic mice and heterozygous (SOD2+/-) knockout mice.

Authors:  J Ju; W Chen; Y Lai; L Wang; H Wang; W J Chen; X Zhao; H Ye; Y Li; Y Zhang
Journal:  Braz J Med Biol Res       Date:  2017-07-10       Impact factor: 2.590

9.  The effect of Astragalus polysaccharides on attenuation of diabetic cardiomyopathy through inhibiting the extrinsic and intrinsic apoptotic pathways in high glucose -stimulated H9C2 cells.

Authors:  Shuqin Sun; Shuo Yang; Min Dai; Xiujuan Jia; Qiyan Wang; Zheng Zhang; Yongjun Mao
Journal:  BMC Complement Altern Med       Date:  2017-06-13       Impact factor: 3.659

10.  The critical role of Astragalus polysaccharides for the improvement of PPARα [ correction of PPRAα]-mediated lipotoxicity in diabetic cardiomyopathy.

Authors:  Wei Chen; Yanping Xia; Xuelan Zhao; Hao Wang; Wenjie Chen; Maohua Yu; Yiming Li; Hongying Ye; Yu Zhang
Journal:  PLoS One       Date:  2012-10-01       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.